You are here: Industry Insights > Pharma in China

News List

The Road to Long-acting Injectables Spuer 203
May 23, 2024
As a complex formulation, long-acting injectables are a class of long-acting sustained-release formulations in which a sufficient amount of drug is injected into the body and slowly released to allow the drug to continue to produce treatment.
Research Progress on the Pharmacological Activity and Structural Modification of Sinomenine Xiaonisha
May 23, 2024
Sinomenine is an isoquinoline alkaloid isolated from Qingfeng vine, a traditional Chinese medicine for the treatment of rheumatic diseases.
The Classification of Sesquiterpene Compounds and Their Research Progress Xiaomichong
May 23, 2024
Terpenoids are an important part of natural organic compounds, and there are currently more than 50,000 reported terpenoid structures.
Effect of Intestinal Flora on Active Ingredients in Traditional Chinese Medicine Xiaomichong
May 23, 2024
The gut microbiota can produce a variety of enzymes, mainly α-rhamnosidase, β-glucosidase, β-galactosidase, nitroreductase, 7α-hydroxylase, protease, and a variety of carbohydrate-active enzymes，CAZymes .
Selection of Commercial Models for Innovative Drugs WND
May 21, 2024
Marketing is the crucial stage in the life cycle of a pharmaceutical product, directly determining the success of its development. Large pharmaceutical companies typically possess a robust sales system, giving them a unique advantage in terms of first-mov
Huashan Is Not the Only Road: A Brief Discussion on the Development Opportunities of Pharmaceutical Dosage Form Improvement Spur 203
May 21, 2024
It's difficult to create innovative drugs with high thresholds, and generics are highly competitive with few barriers, leading to excessive competition.
Inventory of New Drug Targets in 2023 roger
May 21, 2024
In 2023, 49 new drugs received their first approval in the United States, the European Union, and Japan.
MSD, BI and CStone Pharmaceuticals Made Significant Investments in ROR1 ADC Far-away from the Crowd
May 06, 2024
Ipsen Invested USD 900 Million to Introduce Sutro Biopharma ADC.
From Ruxolitinib to Upadacitinib, the USD 5 Billion Blue Ocean Market Ushers a Fierce Battle of JAK Inhibitors Spuer 203
May 06, 2024
Medical System from Incyte has initiated Phase III clinical trials of vitiligo in China.
From CDMO Pharmaceutical Crisaborole First Generic Drug, Look at the Domestic PDE-4 Inhibitor R&D Development Layout Xiaobin
May 06, 2024
The NMPA official website showed that Zhejiang CDMO Pharmaceutical had submitted an application for the marketing application of crisaborole ointment as a generic drug and it was accepted by the Center for Drug Evaluation.